CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 180 target
Drug / intervention
Immunonutrition +1 moredietary
Likely dose
Not stated in record
Key inclusion· 5
  • Confirmed histological diagnosis of metastatic non-small cell lung cancer
  • First-line treatment with immunotherapy alone or in combination with chemotherapy for metastatic disease
  • Written informed consent required
  • Ability to administer oral supplements and immunotherapy with or without chemotherapy
Key exclusion· 3
  • Age <18 years
  • Inability to sign informed consent
  • Indication to or ongoing artificial nutrition support or incapacity to consume oral nutritional supplements

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05384873
NCT05384873N/ARecruitingOn TrackUpdated 14mo ago
Long Recruiting

Multicentre, Randomised, Open-label, Parallel-group Trial to Evaluate Immunonutrition in Improving Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer, Undergoing Systematic Nutritional Counseling

Fondazione IRCCS Policlinico San Matteo di Pavia·interventional·Posted May 20, 2022·Updated May 1, 2025

In Brief

A clinical study evaluating Immunonutrition and Control dietary intervention for Lung Cancer, Nonsmall Cell. Currently recruiting, targeting 180 participants across 1 site.

Detailed Summary

The present study was designed to evaluate the efficacy of the early systematic provision of oral nutritional supplements enriched in immunonutrients in non-small lung cancer patients undergoing immunotherapy and receiving nutritional counseling

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesItaly

Timeline

N/ARecruiting
20232024202520262027
First PostedMay 20, 2022
Enrollment StartJun 1, 2023
Primary CompletionJul 31, 2026
Study CompletionJul 31, 2027
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 4.1 years agoPrimary completion in 29 days

Interventions

Immunonutritiondietary

In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Oral Impact®). The intervention will start approximately two weeks before anticancer treatment initiation and will continue up to first disease re-assessment (12-14 weeks) and prolonged according to patient's needs

Control dietary interventionother

Patients will receive nutritional counseling as standard of care. Nutritional counseling may comprise the use of oral nutritional supplements (ONS), which are usually prescribed when patients are unable to maintain satisfactory spontaneous food intake (less than 50% of the requirement for more than one week or only 50-75% of the requirement for more than two weeks). Therefore, in this arm the use of isonitrogenous standard blend ONS will be considered according to the regular assessment of food intake.